New advances of artificial intelligence in the diagnosis of non-alcoholic fatty liver disease.
10.3760/cma.j.cn50113-20210806-00380
- Author:
Xiao He LI
1
;
Feng LIU
1
;
Hui Ying RAO
1
Author Information
1. Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing 100044, China.
- Publication Type:Review
- MeSH:
Artificial Intelligence;
Biopsy/methods*;
Humans;
Liver/pathology*;
Liver Cirrhosis/pathology*;
Liver Neoplasms/pathology*;
Non-alcoholic Fatty Liver Disease/pathology*
- From:
Chinese Journal of Hepatology
2022;30(4):443-446
- CountryChina
- Language:Chinese
-
Abstract:
Artificial intelligence (AI) refers to the use of computer programs to simulate and extend human intelligence, and has application prospects in the diagnosis and treatment of diseases. This review focuses on the research status of the screening and diagnosis of NAFLD and nonalcoholic steatohepatitis using artificial intelligence technology, electronic health record data, multi-omics prediction models, image recognition technology based on liver imaging and pathological biopsy, and new drugs research and development, with a view to provide new ideas for the diagnosis and treatment.
